These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 7707492)

  • 21. Pharmacodynamics and pharmacokinetics of phenylbutazone in calves.
    Arifah AK; Lees P
    J Vet Pharmacol Ther; 2002 Aug; 25(4):299-309. PubMed ID: 12213119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ketorolac Is Not More Effective Than Flunixin Meglumine or Phenylbutazone in Reducing Foot Pain in Horses.
    Grady SE; Lescun TB; Moore GE; Cooper BR; Davern AJ; Brunner TJ; Taylor SD
    J Equine Vet Sci; 2020 Nov; 94():103204. PubMed ID: 33077087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure.
    Fourie T; Cromarty D; Duncan N; Wolter K; Naidoo V
    PLoS One; 2015; 10(10):e0141419. PubMed ID: 26512724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of an endurance-like exercise on the disposition and detection time of phenylbutazone and dexamethasone in the horse: application to medication control.
    Authie EC; Garcia P; Popot MA; Toutain PL; Doucet M
    Equine Vet J; 2010 Apr; 42(3):240-7. PubMed ID: 20486981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The tissue cage in dogs--a pharmacologic model for the representation of plasma and tissue kinetics].
    Scherkl R; Hashem A; Frey HH
    Dtsch Tierarztl Wochenschr; 1996 May; 103(5):174-7. PubMed ID: 8964239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A non-invasive and quantitative method for the study of tissue injury caused by intramuscular injection of drugs in horses.
    Toutain PL; Lassourd V; Costes G; Alvinerie M; Bret L; Lefebvre HP; Braun JP
    J Vet Pharmacol Ther; 1995 Jun; 18(3):226-35. PubMed ID: 7674460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The concentration changes of different phenylbutazone formulations in horse plasma].
    Keller H; Hashem A
    Dtsch Tierarztl Wochenschr; 1996 Jun; 103(6):224-30. PubMed ID: 8766906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phenylbutazone blood and urine concentrations, pharmacokinetics, and effects on biomarkers of inflammation in horses following intravenous and oral administration of clinical doses.
    Knych HK; Arthur RM; McKemie DS; Seminoff K; Hamamoto-Hardman B; Kass PH
    Drug Test Anal; 2019 Jun; 11(6):792-803. PubMed ID: 30499176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disposition of flunixin meglumine injectable preparation administered orally to healthy horses.
    Pellegrini-Masini A; Poppenga RH; Sweeney RW
    J Vet Pharmacol Ther; 2004 Jun; 27(3):183-6. PubMed ID: 15189304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disposition and tolerance of suxibuzone in horses.
    Jaraiz MV; Rodriguez C; San Andres MD; Gonzalez F; San Andres MI
    Equine Vet J; 1999 Sep; 31(5):411-6. PubMed ID: 10505957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma and serum concentrations of phenylbutazone and oxyphenbutazone in racing Thoroughbreds 24 hours after treatment with various dosage regimens.
    Soma LR; Sams R; Duer W; Tobin T; Woodward C; McDonald J
    Am J Vet Res; 1985 Apr; 46(4):932-8. PubMed ID: 4014842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of methocarbamol and phenylbutazone in exercised Thoroughbred horses.
    Knych HK; Stanley SD; Seminoff KN; McKemie DS; Kass PH
    J Vet Pharmacol Ther; 2016 Oct; 39(5):469-77. PubMed ID: 26924025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of flunixin meglumine, phenylbutazone and a selective thromboxane synthetase inhibitor (UK-38,485) on thromboxane and prostacyclin production in healthy horses.
    Hardee MM; Moore JN; Hardee GE
    Res Vet Sci; 1986 Mar; 40(2):152-6. PubMed ID: 3517992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disposition and excretion of flunixin meglumine in horses.
    Soma LR; Behrend E; Rudy J; Sweeney RW
    Am J Vet Res; 1988 Nov; 49(11):1894-8. PubMed ID: 3247913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of flunixin meglumine in healthy foals less than twenty-four hours old.
    Crisman MV; Wilcke JR; Sams RA
    Am J Vet Res; 1996 Dec; 57(12):1759-61. PubMed ID: 8950431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Practical implications of pharmacokinetic and pharmacodynamic (PK/PD) modelling of drug dose regimens.
    Baggot JD
    Equine Vet J; 1995 Jul; 27(4):245-6. PubMed ID: 8536659
    [No Abstract]   [Full Text] [Related]  

  • 37. The intramuscular bioavailability of a phenylbutazone preparation in the horse.
    Landuyt J; Delbeke FT; Debackere M
    J Vet Pharmacol Ther; 1993 Dec; 16(4):494-500. PubMed ID: 8126767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of flunixin on cardiorespiratory, plasma lactate and stride length responses to intense treadmill exercise in Standardbred trotters.
    Kallings P; Persson SG; Essén-Gustavsson B
    Equine Vet J Suppl; 2010 Nov; (38):618-23. PubMed ID: 21059070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phenylbutazone in racing greyhounds: plasma and urinary residues 24 and 48 hours after a single intravenous administration.
    Mills PC; Ng JC; Skelton KV; Seawright AA; Auer DE
    Aust Vet J; 1995 Aug; 72(8):304-8. PubMed ID: 8579562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distribution of flunixin meglumine and firocoxib into aqueous humor of horses.
    Hilton HG; Magdesian KG; Groth AD; Knych H; Stanley SD; Hollingsworth SR
    J Vet Intern Med; 2011; 25(5):1127-33. PubMed ID: 21781166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.